FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035803003> ?p ?o ?g. }

• W3035803003 endingPage "104" @default.
• W3035803003 startingPage "104" @default.
• W3035803003 abstract "Introduction: Acute promyelocytic leukemia (APL) is defined by unique morphological features, typically abnormal promyelocytes containing azurophilic granules. Genomic basis of APL is characterized by the translocation t(15;17)(q22;q21), inducing fusions between promyelocytic leukemia (PML) and retinoic acid receptor-a (RARA). APL cells with PML-RARA respond to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), and recent clinical trials have achieved excellent outcome for typical APL with PML-RARA . Although a certain fraction of APL cases lacks PMR-RARA, most of them had translocation including RARA and other genes, namely, PLZF, NPM, and TBL1XR1 . Eventually, all known APL-associated translocations involve RARA, accounting for 99% of APL. However, RARA rearrangement is unable to be detected in the rest of APL cases, and molecular mechanisms underlying this small subset is still unclear. We here analyzed APL cases without RARA translocation, and identified a novel RARB fusion in the majority of patients with RARA -negative APL. Materials and methods: We first performed whole-genome sequencing to identify potential genomic alterations in a case with RARA -negative APL, and successfully identified an in-frame fusion between TBL1XR1 and RARB . As RARB, encodes retinoic acid receptor-b, and RARA are both members of the nuclear receptor superfamily, we further searched for RARB alterations in additional 4 cases diagnosed APL morphologically lacking RARA translocation, using whole-transcriptome sequencing, RT-PCR, and FISH, according to sample availability. The five RARA -negative APL cases consist of one male and four females, and the median age of the cases were 3 years (range, 2-4 years of age). All cases were refractory to ATRA, and multiagent chemotherapy was given as acute myeloblastic leukemia but four cases suffered relapse or failed to achieve remission. To investigate functional effect of this novel fusion on leukemogenesis, we then transduced cell lines, bone marrow cells of mice, and human cord blood with TBL1XR1-RARB, RARB, and PML-RARA . Influence of all-trans retinoic acid (ATRA), arsenic trioxide (ATO) was also assessed. Results: Four of the five (80%) cases had RARB translocations (three had the TBL1XR1-RARB fusion (Figure), and one had RARB rearrangement detected by FISH although partner gene of the case could not be determined). The novel fusion protein, TBL1XR1-RARB, could homodimerize, and diminished transcriptional activity with a dominant negative effect on both RARA and RARB. Transduced U937 cell lines with TBL1XR1-RARB showed cell differentiation with increased expression of CD11b when treated with ATRA, and neutrophil differentiation was confirmed by morphology. These effect of TBL1XR1-RARB were cancelled by administration of ATRA, although the impact was partial compared to that of PML-RARA. ATO, leading PML-RARA degradation by biding PML, could not affect TBL1XR1-RARB transduced cell lines. Colony replating assay demonstrated that this TBL1XR1-RARB could enhance replating ability of murine bone marrow. Differentiation of human cord blood was blocked by TBL1XR1-RARB, as well as PML-RAR, which was also confirmed by morphological features. Conclusion: We found that the majority of RARA-negative APL had RARB translocation, defining a novel genetic subgroup in APL. Unlike wild type RARB, the TBL1XR1-RARB proteins homodimerize, suppress retinoic acid pathway, and are confirmed as having oncogenic potency, as well as PML-RARA. Our study confirmed that dysregulation in retinoic acid pathway was a hallmark of APL, however, response to ATRA was partial, which is concordant to clinical resistance to ATRA of RARA -negative APL. Thus, in the context of precision medicine, RARB alteration should be screened for RARA -negative APL cases. Disclosures Kitamura: Daiichi Sankyo: Research Funding." @default.
• W3035803003 created "2020-06-25" @default.
• W3035803003 creator A5000253239 @default.
• W3035803003 creator A5003431914 @default.
• W3035803003 creator A5006474917 @default.
• W3035803003 creator A5016009926 @default.
• W3035803003 creator A5016886169 @default.
• W3035803003 creator A5018787868 @default.
• W3035803003 creator A5021592619 @default.
• W3035803003 creator A5029932023 @default.
• W3035803003 creator A5036060858 @default.
• W3035803003 creator A5036428305 @default.
• W3035803003 creator A5038099871 @default.
• W3035803003 creator A5039143017 @default.
• W3035803003 creator A5041204580 @default.
• W3035803003 creator A5042588749 @default.
• W3035803003 creator A5047436057 @default.
• W3035803003 creator A5054497666 @default.
• W3035803003 creator A5054682762 @default.
• W3035803003 creator A5058882740 @default.
• W3035803003 creator A5061151189 @default.
• W3035803003 creator A5063390528 @default.
• W3035803003 creator A5064103518 @default.
• W3035803003 creator A5073119979 @default.
• W3035803003 creator A5073839222 @default.
• W3035803003 creator A5078387402 @default.
• W3035803003 creator A5078968582 @default.
• W3035803003 creator A5081837183 @default.
• W3035803003 creator A5083816730 @default.
• W3035803003 creator A5086241483 @default.
• W3035803003 creator A5091854985 @default.
• W3035803003 date "2017-12-07" @default.
• W3035803003 modified "2023-10-11" @default.
• W3035803003 title "RARB Translocations in Acute Promyelocytic Leukemia without Rara translocation" @default.
• W3035803003 doi "https://doi.org/10.1182/blood.v130.suppl_1.104.104" @default.
• W3035803003 hasPublicationYear "2017" @default.
• W3035803003 type Work @default.
• W3035803003 sameAs 3035803003 @default.
• W3035803003 citedByCount "0" @default.
• W3035803003 crossrefType "journal-article" @default.
• W3035803003 hasAuthorship W3035803003A5000253239 @default.
• W3035803003 hasAuthorship W3035803003A5003431914 @default.
• W3035803003 hasAuthorship W3035803003A5006474917 @default.
• W3035803003 hasAuthorship W3035803003A5016009926 @default.
• W3035803003 hasAuthorship W3035803003A5016886169 @default.
• W3035803003 hasAuthorship W3035803003A5018787868 @default.
• W3035803003 hasAuthorship W3035803003A5021592619 @default.
• W3035803003 hasAuthorship W3035803003A5029932023 @default.
• W3035803003 hasAuthorship W3035803003A5036060858 @default.
• W3035803003 hasAuthorship W3035803003A5036428305 @default.
• W3035803003 hasAuthorship W3035803003A5038099871 @default.
• W3035803003 hasAuthorship W3035803003A5039143017 @default.
• W3035803003 hasAuthorship W3035803003A5041204580 @default.
• W3035803003 hasAuthorship W3035803003A5042588749 @default.
• W3035803003 hasAuthorship W3035803003A5047436057 @default.
• W3035803003 hasAuthorship W3035803003A5054497666 @default.
• W3035803003 hasAuthorship W3035803003A5054682762 @default.
• W3035803003 hasAuthorship W3035803003A5058882740 @default.
• W3035803003 hasAuthorship W3035803003A5061151189 @default.
• W3035803003 hasAuthorship W3035803003A5063390528 @default.
• W3035803003 hasAuthorship W3035803003A5064103518 @default.
• W3035803003 hasAuthorship W3035803003A5073119979 @default.
• W3035803003 hasAuthorship W3035803003A5073839222 @default.
• W3035803003 hasAuthorship W3035803003A5078387402 @default.
• W3035803003 hasAuthorship W3035803003A5078968582 @default.
• W3035803003 hasAuthorship W3035803003A5081837183 @default.
• W3035803003 hasAuthorship W3035803003A5083816730 @default.
• W3035803003 hasAuthorship W3035803003A5086241483 @default.
• W3035803003 hasAuthorship W3035803003A5091854985 @default.
• W3035803003 hasConcept C104317684 @default.
• W3035803003 hasConcept C119775778 @default.
• W3035803003 hasConcept C120197328 @default.
• W3035803003 hasConcept C138626823 @default.
• W3035803003 hasConcept C153911025 @default.
• W3035803003 hasConcept C206936463 @default.
• W3035803003 hasConcept C2776601000 @default.
• W3035803003 hasConcept C2778461978 @default.
• W3035803003 hasConcept C2781121885 @default.
• W3035803003 hasConcept C502942594 @default.
• W3035803003 hasConcept C54355233 @default.
• W3035803003 hasConcept C86803240 @default.
• W3035803003 hasConceptScore W3035803003C104317684 @default.
• W3035803003 hasConceptScore W3035803003C119775778 @default.
• W3035803003 hasConceptScore W3035803003C120197328 @default.
• W3035803003 hasConceptScore W3035803003C138626823 @default.
• W3035803003 hasConceptScore W3035803003C153911025 @default.
• W3035803003 hasConceptScore W3035803003C206936463 @default.
• W3035803003 hasConceptScore W3035803003C2776601000 @default.
• W3035803003 hasConceptScore W3035803003C2778461978 @default.
• W3035803003 hasConceptScore W3035803003C2781121885 @default.
• W3035803003 hasConceptScore W3035803003C502942594 @default.
• W3035803003 hasConceptScore W3035803003C54355233 @default.
• W3035803003 hasConceptScore W3035803003C86803240 @default.
• W3035803003 hasLocation W30358030031 @default.
• W3035803003 hasOpenAccess W3035803003 @default.
• W3035803003 hasPrimaryLocation W30358030031 @default.
• W3035803003 hasRelatedWork W1966895669 @default.
• W3035803003 hasRelatedWork W2000281122 @default.

• next